| Cellulaze™, a minimally-invasive laser technology designed for the long-term reduction of cellulite, has received clearance in the EU, Canada, Korea & Australia. In the United States the US Food and Drug Administration reviewed and cleared the device in early 2012. Cellulite is a stubborn problem troubling over 80% of women. Typically a variety of treatments have traditionally been employed to treat cellulite, with varying results. Due to the high level of patient demand for an effective treatment for cellulite, hopes for the Cellulaze are high. According to reports, Cellulaze is performed under local anesthesia with a small cannula being inserted under the skin. Laser energy is then directed to the treatment area, targeting the cellulite. Laser energy has been used for years to smooth skin and remove fat cells. Cynosure, Inc. (NASDAQ: CYNO), marker of Cellulaze™, has had prior success with its SmartLipo™ device, a minimally-invasive fat reduction device. Cynosure is a leader in the development and distribution of laser and light-based technologies for the improvement of aesthetic issues. |